INCOME TAXES - Deferred tax asset (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Deferred tax assets | ||
| Net operating loss carryforwards | $ 3,359,183 | $ 1,594,650 |
| Share-based compensation | 2,262,381 | 1,149,720 |
| Research and development credit carryforwards | 141,671 | 105,881 |
| Capitalized research and development | 1,347,028 | |
| Gross deferred tax assets | 7,110,263 | 2,850,251 |
| Less valuation allowance | (7,110,263) | $ (2,850,251) |
| Capitalized research and development | $ 4,300,000 |
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The fair value of capitalized costs of a research and development nature that were acquired during the period in a transaction other than a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|